Head to Head Contrast: Miravant Medical Technologies (OTCMKTS:MRVT) and Vaxart (OTCMKTS:VXRT)

Vaxart (OTCMKTS:VXRT) and Miravant Medical Technologies (OTCMKTS:MRVT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings.

Profitability

This table compares Vaxart and Miravant Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxart	15.88%	53.04%	20.85%
Miravant Medical Technologies	N/A	N/A	N/A

Valuation and Earnings

This table compares Vaxart and Miravant Medical Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxart	$237.26 million	0.52	$16.33 million	$0.16	3.19
Miravant Medical Technologies	N/A	N/A	N/A	N/A	N/A

Vaxart has higher revenue and earnings than Miravant Medical Technologies.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Vaxart and Miravant Medical Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxart	0	1	0	0	2.00
Miravant Medical Technologies	0	0	0	0	0.00

Given Miravant Medical Technologies’ higher possible upside, analysts plainly believe Miravant Medical Technologies is more favorable than Vaxart.

Insider & Institutional Ownership

18.0% of Vaxart shares are held by institutional investors. 2.8% of Vaxart shares are held by company insiders. Comparatively, 17.1% of Miravant Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Vaxart beats Miravant Medical Technologies on 6 of the 8 factors compared between the two stocks.

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

About Miravant Medical Technologies

Miravant Medical Technologies Inc. operates as a pharmaceutical research and development company. The company develops PhotoPoint, a photodynamic therapy that responds to light destroying cancerous cells; and manufactures light producing and light delivery devices. Its products include PHOTREX for the treatment of wet age-related macular degeneration or AMD; MV9411, a photoreactive drug for the treatment of plaque psoriasis; MV0633 for the treatment of atherosclerosis, atherosclerotic vulnerable plaque, and restenosis; MV2101 for the treatment of vascular access graft disease in hemodialysis patients; and MV6401 for the treatment of solid tumors. Miravant Medical Technologies Inc. was formerly known as PDT, Inc. and changed its name to Miravant Medical Technologies Inc. in September 1997. The company was founded in 1989 and is headquartered in Santa Barbara, California.